Join Growin Stock Community!

Acumen pharmaceuticals, inc.ABOS.US Overview

US StockHealthcare
(No presentation for ABOS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ABOS AI Insights

ABOS Overall Performance

ABOS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ABOS Recent Performance

-1.28%

Acumen pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ABOS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ABOS Key Information

ABOS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ABOS Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Price of ABOS

ABOS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ABOS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.20
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
538.78
PB Ratio
2.04
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.20
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
538.78
PB Ratio
2.04
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ABOS's latest earnings report released?

    The most recent financial report for Acumen pharmaceuticals, inc. (ABOS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ABOS's short-term business performance and financial health. For the latest updates on ABOS's earnings releases, visit this page regularly.

  • How much debt does ABOS have?

    As of the end of the reporting period, Acumen pharmaceuticals, inc. (ABOS) had total debt of 30.65M, with a debt ratio of 0.22. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ABOS have?

    At the end of the period, Acumen pharmaceuticals, inc. (ABOS) held Total Cash and Cash Equivalents of 47.06M, accounting for 0.33 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ABOS's EPS continuing to grow?

    According to the past four quarterly reports, Acumen pharmaceuticals, inc. (ABOS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.44. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ABOS?

    Acumen pharmaceuticals, inc. (ABOS)'s Free Cash Flow (FCF) for the period is -30.49M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 23.96% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ABOS?

    The latest valuation data shows Acumen pharmaceuticals, inc. (ABOS) has a Price-To-Earnings (PE) ratio of -0.89 and a Price/Earnings-To-Growth (PEG) ratio of 0.03. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.